Skip to main content

Advertisement

Table 3 Cell viability IC50 values for KG-1, U-937, RAJI, PC-3, MDA-MB-231, RPMI1788, and non-proliferating or proliferating PBM cells after 48 h of treatment with MC3353 or SGI-1027

From: Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells

Compound IC50 ± SDa, μM (Selectivity indexb)
KG-1 U-937 RAJI PC-3 MDA-MB-231 RPMI1788 PBMCs PHA_PBMCsc
MC3353 0.3 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 0.9 ± 0.4 0.9 ± 0.7 2.4 ± 0.2 8.9 ± 4.2 4.6 ± 0.5
(IC50 RPMI1788/IC50 cell line) (7.2) (6.6) (6.3) (2.7) (2.6) (NA) (NA) (NA)
(IC50 PBMCs/IC50 cell line) (26.2) (24.0) (23.1) (9.8) (9.7) (NA) (NA) (NA)
(IC50 PHA_PBMCs/IC50 cell line) (13.5) (12.4) (11.9) (5.1) (5.0) (NA) (NA) (NA)
SGI-1027 3.6 ± 0.6 1.7 ± 1.5 7.8 ± 0.7 5.0 ± 0.6 8.5 ± 7.2 6.7 ± 1.3 18.1 ± 6.8 ND
(IC50 RPMI1788/IC50 cell line) (1.9) (3.9) (0.9) (1.3) (0.8) (NA) (NA) (NA)
(IC50 PBMCs/IC50 cell line) (5) (10.6) (2.3) (3.6) (2.1) (NA) (NA) (NA)
  1. SD standard deviation, NA not applicable, ND not determined
  2. aData are the mean of at least three independent experiments
  3. bDifferential toxicity was calculated as the ratio of the IC50 normal cells (either PBMCs or RMPI1788) to the IC50 neoplastic cells
  4. cPHA_PBMCs: phytohemagglutinin-stimulated PBMCs